APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripheral Neuritis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peripheral Neuritis Treatment Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchPeripheral Neuritis Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripheral Neuritis Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Peripheral Neuritis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripheral Neuritis Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripheral Neuritis Treatment Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peripheral Neuritis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peripheral Neuritis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peripheral Neuritis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peripheral Neuritis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peripheral Neuritis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peripheral Neuritis Treatment market include Teva Pharmaceuticals, Sanofi, Johnson & Johnson, Novartis, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Biogen and Baxter Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Peripheral Neuritis Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peripheral Neuritis Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peripheral Neuritis Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peripheral Neuritis Treatment market.

Peripheral Neuritis Treatment Segment by Company

Teva Pharmaceuticals

Sanofi

Johnson & Johnson

Novartis

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Biogen

Baxter Healthcare

Depomed

Bristol-Myers Squibb

Peripheral Neuritis Treatment Segment by Type

Idiopathic Peripheral Neuropathy (IPN)

Diabetic Peripheral Neuropathy (DPN)

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Others

Peripheral Neuritis Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Peripheral Neuritis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peripheral Neuritis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peripheral Neuritis Treatment key companies, revenue, market share, and recent developments.

3. To split the Peripheral Neuritis Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peripheral Neuritis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peripheral Neuritis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Peripheral Neuritis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripheral Neuritis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripheral Neuritis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripheral Neuritis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peripheral Neuritis Treatment industry.

Chapter 3: Detailed analysis of Peripheral Neuritis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peripheral Neuritis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peripheral Neuritis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peripheral Neuritis Treatment Industry Trends Table 2. Peripheral Neuritis Treatment Industry Drivers Table 3. Peripheral Neuritis Treatment Industry Opportunities and Challenges Table 4. Peripheral Neuritis Treatment Industry Restraints Table 5. Global Peripheral Neuritis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peripheral Neuritis Treatment Revenue Share by Company (2021-2026) Table 7. Global Peripheral Neuritis Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peripheral Neuritis Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Peripheral Neuritis Treatment Company, Product Type & Application Table 10. Global Peripheral Neuritis Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peripheral Neuritis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Idiopathic Peripheral Neuropathy (IPN) Table 15. Significant Companies of Diabetic Peripheral Neuropathy (DPN) Table 16. Significant Companies of Chemotherapy-induced Peripheral Neuropathy (CIPN) Table 17. Significant Companies of Others Table 18. Global Peripheral Neuritis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Peripheral Neuritis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Peripheral Neuritis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Peripheral Neuritis Treatment Sales Value Share by Type (2021-2026) Table 22. Global Peripheral Neuritis Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Pharmacies Table 24. Significant Companies of Online Pharmacies Table 25. Significant Companies of Retail Pharmacies Table 26. Global Peripheral Neuritis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peripheral Neuritis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Peripheral Neuritis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Peripheral Neuritis Treatment Sales Value Share by Application (2021-2026) Table 30. Global Peripheral Neuritis Treatment Sales Value Share by Application (2027-2032) Table 31. Global Peripheral Neuritis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peripheral Neuritis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Peripheral Neuritis Treatment Sales Value Share by Region (2021-2026) Table 34. Global Peripheral Neuritis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Peripheral Neuritis Treatment Sales Value Share by Region (2027-2032) Table 36. Global Peripheral Neuritis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Peripheral Neuritis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Peripheral Neuritis Treatment Sales Value Market Share by Country (2021-2026) Table 39. Global Peripheral Neuritis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Peripheral Neuritis Treatment Sales Value Market Share by Country (2027-2032) Table 41. Teva Pharmaceuticals Company Information Table 42. Teva Pharmaceuticals Business Overview Table 43. Teva Pharmaceuticals Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Teva Pharmaceuticals Peripheral Neuritis Treatment Product Portfolio Table 45. Teva Pharmaceuticals Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sanofi Peripheral Neuritis Treatment Product Portfolio Table 50. Sanofi Recent Development Table 51. Johnson & Johnson Company Information Table 52. Johnson & Johnson Business Overview Table 53. Johnson & Johnson Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Johnson & Johnson Peripheral Neuritis Treatment Product Portfolio Table 55. Johnson & Johnson Recent Development Table 56. Novartis Company Information Table 57. Novartis Business Overview Table 58. Novartis Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Novartis Peripheral Neuritis Treatment Product Portfolio Table 60. Novartis Recent Development Table 61. Eli Lilly and Company Company Information Table 62. Eli Lilly and Company Business Overview Table 63. Eli Lilly and Company Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Eli Lilly and Company Peripheral Neuritis Treatment Product Portfolio Table 65. Eli Lilly and Company Recent Development Table 66. Pfizer Company Information Table 67. Pfizer Business Overview Table 68. Pfizer Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Pfizer Peripheral Neuritis Treatment Product Portfolio Table 70. Pfizer Recent Development Table 71. GlaxoSmithKline Company Information Table 72. GlaxoSmithKline Business Overview Table 73. GlaxoSmithKline Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. GlaxoSmithKline Peripheral Neuritis Treatment Product Portfolio Table 75. GlaxoSmithKline Recent Development Table 76. Biogen Company Information Table 77. Biogen Business Overview Table 78. Biogen Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Biogen Peripheral Neuritis Treatment Product Portfolio Table 80. Biogen Recent Development Table 81. Baxter Healthcare Company Information Table 82. Baxter Healthcare Business Overview Table 83. Baxter Healthcare Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Baxter Healthcare Peripheral Neuritis Treatment Product Portfolio Table 85. Baxter Healthcare Recent Development Table 86. Depomed Company Information Table 87. Depomed Business Overview Table 88. Depomed Peripheral Neuritis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Depomed Peripheral Neuritis Treatment Product Portfolio Table 90. Depomed Recent Development Table 91. Bristol-Myers Squibb Company Information Table 92. Bristol-Myers Squibb Business Overview Table 93. Bristol-Myers Squibb Peripheral Neuritis Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Bristol-Myers Squibb Peripheral Neuritis Treatment Product Portfolio Table 95. Bristol-Myers Squibb Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Peripheral Neuritis Treatment Product Image Figure 2. Global Peripheral Neuritis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripheral Neuritis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Peripheral Neuritis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Idiopathic Peripheral Neuropathy (IPN) Image Figure 8. Diabetic Peripheral Neuropathy (DPN) Image Figure 9. Chemotherapy-induced Peripheral Neuropathy (CIPN) Image Figure 10. Others Image Figure 11. Global Peripheral Neuritis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Peripheral Neuritis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Peripheral Neuritis Treatment Sales Value Share by Type (2021-2032) Figure 14. Hospital Pharmacies Image Figure 15. Online Pharmacies Image Figure 16. Retail Pharmacies Image Figure 17. Global Peripheral Neuritis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Peripheral Neuritis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Peripheral Neuritis Treatment Sales Value Share by Application (2021-2032) Figure 20. Global Peripheral Neuritis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Peripheral Neuritis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Peripheral Neuritis Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. North America Peripheral Neuritis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Peripheral Neuritis Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Peripheral Neuritis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Peripheral Neuritis Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Peripheral Neuritis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Peripheral Neuritis Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. South America Peripheral Neuritis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Peripheral Neuritis Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Peripheral Neuritis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Idiopathic Peripheral Neuropathy (IPN)
  • Diabetic Peripheral Neuropathy (DPN)
  • Chemotherapy-induced Peripheral Neuropathy (CIPN)
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Baxter Healthcare
  • Depomed
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peripheral Neuritis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peripheral Neuritis Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peripheral Neuritis Treatment Market Dynamics
  1. 2.1 Peripheral Neuritis Treatment Industry Trends
  2. 2.2 Peripheral Neuritis Treatment Industry Drivers
  3. 2.3 Peripheral Neuritis Treatment Industry Opportunities and Challenges
  4. 2.4 Peripheral Neuritis Treatment Industry Restraints
3 Peripheral Neuritis Treatment Market by Company
  1. 3.1 Global Peripheral Neuritis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Peripheral Neuritis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Peripheral Neuritis Treatment Company Ranking (2024-2026)
  4. 3.4 Global Peripheral Neuritis Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Peripheral Neuritis Treatment Company Product Type and Application
  6. 3.6 Global Peripheral Neuritis Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peripheral Neuritis Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peripheral Neuritis Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peripheral Neuritis Treatment Market by Type
  1. 4.1 Peripheral Neuritis Treatment Type Introduction
  2. 4.1.1 Idiopathic Peripheral Neuropathy (IPN)
  3. 4.1.2 Diabetic Peripheral Neuropathy (DPN)
  4. 4.1.3 Chemotherapy-induced Peripheral Neuropathy (CIPN)
  5. 4.1.4 Others
  6. 4.2 Global Peripheral Neuritis Treatment Sales Value by Type
  7. 4.2.1 Global Peripheral Neuritis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Peripheral Neuritis Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Peripheral Neuritis Treatment Sales Value Share by Type (2021-2032)
5 Peripheral Neuritis Treatment Market by Application
  1. 5.1 Peripheral Neuritis Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Peripheral Neuritis Treatment Sales Value by Application
  6. 5.2.1 Global Peripheral Neuritis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peripheral Neuritis Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Peripheral Neuritis Treatment Sales Value Share by Application (2021-2032)
6 Peripheral Neuritis Treatment Regional Value Analysis
  1. 6.1 Global Peripheral Neuritis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peripheral Neuritis Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peripheral Neuritis Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peripheral Neuritis Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peripheral Neuritis Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Peripheral Neuritis Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peripheral Neuritis Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Peripheral Neuritis Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peripheral Neuritis Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peripheral Neuritis Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peripheral Neuritis Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Peripheral Neuritis Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peripheral Neuritis Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peripheral Neuritis Treatment Sales Value Share by Country, 2025 VS 2032
7 Peripheral Neuritis Treatment Country-level Value Analysis
  1. 7.1 Global Peripheral Neuritis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peripheral Neuritis Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peripheral Neuritis Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peripheral Neuritis Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peripheral Neuritis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peripheral Neuritis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peripheral Neuritis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Peripheral Neuritis Treatment Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Peripheral Neuritis Treatment Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Peripheral Neuritis Treatment Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Peripheral Neuritis Treatment Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Eli Lilly and Company
  26. 8.5.1 Eli Lilly and Company Company Information
  27. 8.5.2 Eli Lilly and Company Business Overview
  28. 8.5.3 Eli Lilly and Company Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly and Company Peripheral Neuritis Treatment Product Portfolio
  30. 8.5.5 Eli Lilly and Company Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Peripheral Neuritis Treatment Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Peripheral Neuritis Treatment Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Biogen
  44. 8.8.1 Biogen Company Information
  45. 8.8.2 Biogen Business Overview
  46. 8.8.3 Biogen Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biogen Peripheral Neuritis Treatment Product Portfolio
  48. 8.8.5 Biogen Recent Developments
  49. 8.9 Baxter Healthcare
  50. 8.9.1 Baxter Healthcare Company Information
  51. 8.9.2 Baxter Healthcare Business Overview
  52. 8.9.3 Baxter Healthcare Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Healthcare Peripheral Neuritis Treatment Product Portfolio
  54. 8.9.5 Baxter Healthcare Recent Developments
  55. 8.10 Depomed
  56. 8.10.1 Depomed Company Information
  57. 8.10.2 Depomed Business Overview
  58. 8.10.3 Depomed Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Depomed Peripheral Neuritis Treatment Product Portfolio
  60. 8.10.5 Depomed Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Peripheral Neuritis Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Peripheral Neuritis Treatment Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst